The company said its expenses are forecasted to grow 6% to RON313.7 million, while revenues are seen at RON339.84 million, higher compared with RON318.94 million in 2013.
This year, Antibiotice has no investment plans.
Last year, Antibiotice Iasi said it plans to build new production facilities to develop its medicine portfolio, forecasting investments of EUR40 million by the end of 2020. The first investment within this project, worth EUR10 million, was expected to set off in 2015.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53.02% stake, while regional investment fund SIF Oltenia (SIF5. RO) holds a 10.32% stake. (EUR1=RON4.436)